Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease

Diseases of the Colon and Rectum

Volumn 46, Issue 10 SUPPL., 2003, Pages

  Sawada, Koji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adsorptive apheresis; Conventional medication; Inflammatory cytokines; Inflammatory bowel disease; Intestinal mucosa; Leukocytapheresis; Monocyte; Neutrophil; Prednisolone

Indexed keywords

CORTICOSTEROID; CYTOKINE;

CENTRIFUGATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; ENTERITIS; HUMAN; LEUKAPHERESIS; LEUKOCYTE; MEMBRANE FILTER; NEUTROPHIL; PATHOPHYSIOLOGY; RELAPSE; REMISSION; REVIEW; SAFETY; SURVIVAL TIME;

ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 0142059201     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmapheresis). J Pharmacol Exp Ther 1924;5:625-31.
2. Lanc TA. Continuous-flow leukapheresis for rapid cytoreduction in leukemia. Transfusion 1980;20:455-7.
3. Lowenthal CM. Chronic leukemias: treatment by leukapheresis. Exp Hematol 1977;5(Suppl):73-84.
4. Goldfinger D, Capostagno V, Lowe C, Sacks HJ, Gatti RA. Use of long-term leukapheresis in the treatment of chronic lymphocytic leukemia. Transfusion 1980;20:450-4.
5. Körbling M, Dorken B, Ho AD, Pezzutto A, Hunctein W, Fliedner TM. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67:529-32.
6. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988;71:723-7.
7. Wallance D, Goldfinger D, Lowe C. A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. N Engl J Med 1982;306:1406-10.
8. Hauser SL, Fosburg M, Kevy SV, Weiner HL. Lymphocytapheresis in chronic progressive multiple sclerosis: immunologic and clinical effect. Neurology 1984;34:922-6.
9. Valbonesi M, Garelli S, Zerbi D, Forlani G, Cornelio F, Pelucchetti D. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis. Vox Sang 1982;43:142-6.
10. Kurland J, Franklin S, Goldfinger D. Treatment of renal allograft rejection by exchange plasma-lymphocytapheresis. Transfusion 1980;20:455-7.
11. Valbonesi M. Bruni R. Clinical application of therapeutic erythrocytapheresis (TEA). Transfus Sci 2000;22:183-94.
12. Castro O, Finke CH, Coats D. Improved method for automated red cell exchange in sickle cell disease. J Clin Apheresis 1986;3:93-9.
13. Cahill KM, Benach JL, Reich LM. Red cell exchange: treatment of babesiasis in a splenectomized patient. Transfusion 1981;21:193-8.
14. Taft EG. Management of thrombocytosis. Transfusion 1980;20:235-6.
15. Lazarus HM. Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion 1991;31:122-8.
16. Eshleman JR, Silberstein LE. The development of selective plasmapheresis as a means for specific therapeutic intervention [editorial]. Transfusion 1991;31:96-8.
17. Sawada K, Ohnishi K, Fukui S. Leukocytapheresis therapy performed with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol 1995;30:322-9.
18. Sawada K, Ohnishi K, Kosaka T, Shimoyama T. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apheresis 1997;1:207-11.
19. Kosaka T, Sawada K, Ohnishi K. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med 1999;38:102-11.
20. Fukunaga K, Sawada K, Chikano S. Leukocytapheresis for ulcerative colitis [abstract]. Nippon Rinsho 1999;57:2496-502.
21. Sawada K, Muto T, Shimoyama T. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharma Des 2003;9:307-21.
22. Shimoyama T, Sawada K, Tanaka T. Granulocytapheresis in active ulcerative colitis. A multicenter randomized control study [abstract]. Jpn J Apher 1999;18:117-31.
23. Shimoyama T, Sawada K. Hiwatashi N, Saniabadi A. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001;16:1-9.
24. Hanai H, Watanabe F, Saniabadi A, Matsushita I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002;47:2349-53.
25. Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol 2003;1:28-35.
26. D'Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM. Human neutrophil Fc receptor mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 1994;100:173-9.
27. Edwards SW, Hallett MB. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997;18:320-4.
28. DeForge L, Kenney JS, Jones ML, Warren JS, Remick DG. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. J Immunol 1992:148:2133-41.
29. Wengrower D, Liakim R, Karmeli F, Razin E, Rachmilewitz D. Pathogenesis of ulcerative colitis (UC): enhanced formation of inositol phosphate (IP) and platelet activating factor (PAF). Gastroenterology 1987;92:1691.
30. Fujimori J, Yoshino S. Improvement in rheumatoid arthritis following application of a granulotrap column, G-1. Rheumatol Int 1995;15:175-80.
31. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-93.
32. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000;6:21-33.
33. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978;74:501-3.
34. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-74.
35. Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease. Neuro-immunophysiology of the gastrointestinal mucosa. Ann N Y Acad Sci 1992;664:103-15.
36. Allison MC, Dhillon AP, Lewis WG, Pounder RE, eds. Inflammatory bowel disease. London: Mosby, 1998:91-5.
37. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-6.
38. Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998;42:470-6.
39. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98.
40. Lampinen M, Carlson M, Sangfelt P. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001;46:2004-9.
41. Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
42. Brannigan AE, O'Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-6.
43. Lee, A, Whyte M, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993;54:283-8.
44. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-8.
45. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger GJ. Potential role of the chemokine receptors CXCR3, CXCR4, and the integrin alphaEbeta 7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-47.
46. Gillitzer R. Inflammation in human skin: a model to study chemokine-mediated leukocyte migration in vivo. J Pathol 2001;194:398-405.
47. Wakugawa M, Nakamura K, Kakinuma T, Onai N, Matsushima K, Tamaki K. CC chemokine receptor 4 expression on peripheral blood CD4+ T cells reflects disease activity of atopic dermatitis. J Invest Dermatol 2001;117:188-96.
48. Biswas P, Mantelli B, Hasson H, et al. In vivo modulation of leukocytes trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin Immunol (in press).
49. Bicks RO, Groshart KD. The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol 1989;11:136-8.
50. Lerebours E, Bussel A, Modigliani R. Treatment of Crohn's disease by lymphocytapheresis: a randomized controlled trial. Grouped' Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1994;107:357-61.
51. Ayabe T, Ashida T, Taniguchi M. A pilot study of centrifugal leukocyte apheresis for corticosteroids-resistant active ulcerative colitis. Intern Med 1997;36:322-6.
52. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2002;98:511-2.
53. Kashiwagi N, Saniabadi A, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-41.
54. Ohara M, Saniabadi AR, Hirata I. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21:989-94.
55. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 1998;2:134-41.
56. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
57. Schroeder K, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625-9.
58. Truelove SC, Witts LJ. Cortisone in the treatment of ulcerative colitis: final report on a therapeutic trial. BMJ 1955;2:1041-8.
59. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative colitis? J Clin Gastroenterol 1995;20:280-4.
60. Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: a prospective, randomized, double blind clinical trial. Gastroenterology 1983;85:351-7.
61. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
62. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-8.
63. Stack WA, Long RG, Hawkey CJ. Short and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973-8.
64. Lichtiger S, Present DH, Kombluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-85.
65. Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48-63.
66. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ectotherapeutics. Gastroenterology 2001;120:622-35.
67. Saniabadi AR, Hanai H, Takeuchi K, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dialy 2003;7:48-59.
68. Murphy PM, Baggiolini M, Charo I. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76.